



**Cairo University**  
**Faculty of Veterinary Medicine**  
**Department of Virology**

# **Evaluation of Recombinant HVT-H5 Vaccine**

**A Thesis presented by**

**Ola Youssef M. Youssef**

**Bachelor of Veterinary Medical Science, Cairo University (2011)**

**For the Degree of**

**Master in Veterinary Medical Sciences**

**(Virology)**

**Under Supervision of**

**Prof. Dr. Ahmed Abd El-Ghani El-Sanousi**

**Professor of Virology**

**Faculty of Veterinary Medicine**

**Cairo University**

**Dr. Ayman H. M. EL-Deeb**

**Lecturer of Virology,**

**Faculty of Veterinary Medicine.**

**Cairo University**

**Dr. Samir A. A. Nasif**


**Chief researcher of Poultry Diseases**

**Head of Biotechnology Department**

**Central Lab. For Evaluation  
of Veterinary Biologics.**

**2016**





## Approval Sheet

This is to approve that Thesis presented by

**Ola Youssef M. Youssef**

For the degree of MV.Sc. (Virology) has been approved by the examining committee

**Prof. Dr. Sabry Mohamed Tammam**

Professor of Virology  
Faculty of Veterinary Medicine  
Beni- Sweef University

*Sabry Tam*

**Prof. Dr. Hussein Aly Hussein**

Professor of Virology  
Faculty of Veterinary Medicine,  
Cairo University (Supervisor)

*Hussein Ahmed*

**Prof. Dr- Samir A. A. Nasif**

Chief researcher of poultry Diseases  
Head of Biotechnology Department  
Central Lab .For Evaluation of  
Veterinary Biologics. (Supervisor)

*Samir A. A. Nasif*

**Prof. Dr. Ahmed Abd El-Ghani El-Sanousi**

Professor of Virology  
Faculty of Veterinary Medicine,  
Cairo University (Supervisor)

*Ahmed El-Sanousi*



**Cairo University**  
**Faculty of Veterinary Medicine**  
**Department of Virology**

- **Name : Ola Youssef M. Youssef.**
- **Nationality : Egyptian.**
- **Date of birth: 31/7/1989.**
- **Place of birth: Egypt.**
- **Department: Virology.**
- **Thesis Title: “Evaluation Of Recombinant HVT-H5 Vaccine”.**
- **Supervisors:**
  - **Prof. Dr. Ahmed Abd El-Ghani El-Sanousi**, Professor of virology. Faculty of Vet. Med. Cairo University.
  - **Dr. Ayman H.M. EL-Deeb**, Lecturer of virology, Faculty of Vet. Med. Cairo University.
  - **Dr. Samir Abdel- Moez Nasif**, Chief researcher of Poultry Disease and Head of Biotechnology Department at CLEVB.

**Abstract:** A six vaccine batches selected randomly and coded as A, B, C, D, E, and F were evaluated by identity testing besides regular vaccine safety, purity and potency. The H5 insert identity was evaluated using real-time PCR while the vaccine potency was evaluated using the HVT virus titration, the reduction of virus shedding and challenge test. In this study, the vaccine batches were examined and proved to be identical by quantitative real-time PCR but the in- house ELISA was not significant for H5 gene detection and titration due to using of polyclonal H5 serum. The vaccine purity

**Cairo University**  
**Faculty of Veterinary Medicine**  
**Department of Virology**

was examined by intra allantoic inoculation of vaccine in SPF ECE. The vaccine safety was satisfactory by 10 field doses injection in SPF chicks. The protective efficacy of this vaccine was measured by challenge test parallel to titration of HVT in CEF. The real - time PCR was the most sensitive and specific test for identity testing of this vaccine but, cell-ELISA or H5 ELISA cannot be used to detect H5 gene insert without using monoclonal monospecific H5 serum. The negative result of intra allantoic inoculation of the vaccine in SPF ECE indicates that the vaccine is pure. The infectivity titration of HVT live vector in CEF was correlated with the vaccine potency as show in challenge test of this vaccine batches.

In conclusion, the developed evaluation protocol could depend mainly on q PCR for identity and titration of H5 insert gene in addition to vaccine safety and efficacy.

**Key words:** Recombinant HVT-H5 vaccine, quantitative real-time PCR, intra allantoic inoculation, titration, potency, purity, identity.



## *Dedication*

---

*To my family*

*My kind father, my lovely mother, my  
lovely sisters and brother*

*(A special thank you for being there in  
times of crisis.)*

*To my best friends*



## Acknowledgments

“Praise to Allah, who has guided us to this; and we would never have been guided if Allah had not guided us.”

I would like to express my gratitude and appreciation to the following:

*Prof. Dr. Ahmed Abdel EL-Ghani EL-Sanousi*, Professor of Virology, Faculty of Veterinary Medicine, Cairo University , *Dr. Ayman H.M. EL-Deeb*, Lecturer of Virology Department, Faculty of Veterinary Medicine, Cairo University, and *Dr. Samir Abdel – Moaz Nasif* Chief researcher of Poultry Diseases , Head of Biotechnology Department, CLEVB for their supervision and keen guidance executing this study to its final resort.

*Dr. Nermmen Gouda*, Chief researcher and head of large animal disease vaccines department at CLEVB for her valuable help during this research study.

*Dr. Hanaa Abdel EL- Aziz & Dr. Nermeen Mahmoud* researchers at CLEVB for their practical support in this research study.

*My colloques in CLEVB* for the co-operation and the technical support they offered along the duration of the study period.

Staff members of biotechnology department at CLEVB for their assistance in practical work in this research study.

Staff members of sample receiving office in CLEVB for their assistance in sampling.

I am really feel thankful and record my grateful acknowledgment to *my family especially my kind brother* for encouragement and support me.



# CONTENTS

|                                                                              |            |
|------------------------------------------------------------------------------|------------|
| <b>LIST OF TABLES.....</b>                                                   | <b>I</b>   |
| <b>LIST OF FIGURES.....</b>                                                  | <b>II</b>  |
| <b>LIST OF ABBREVIATIONS.....</b>                                            | <b>III</b> |
| <b>1. INTRODUCTION.....</b>                                                  | <b>1</b>   |
| <b>2. REVIEW OF LITERATURE</b>                                               |            |
| <b>2.1. Historical background of H5N1 .....</b>                              | <b>7</b>   |
| 2.1.1 First record.....                                                      | 7          |
| 2.1.2 History in World.....                                                  | 7          |
| 2.1.3. History in Egypt.....                                                 | 11         |
| <b>2.2. Causative agent.....</b>                                             | <b>17</b>  |
| 2.2.1. Classification and Nomenclature.....                                  | 17         |
| 2.2.1.1 Classification.....                                                  | 17         |
| 2.2.1.1.1. Classification according to pathogenicity.....                    | 18         |
| 2.2.1.2. Strain Nomenclature.....                                            | 19         |
| 2.2.2. Virus morphology.....                                                 | 20         |
| 2.2.3. Genome structure and organization of H5N1 avian influenza.....        | 21         |
| 2.2.4. Proteins encoded by H5N1 avian influenza virus.....                   | 23         |
| 2.2.4.1. Structural proteins.....                                            | 23         |
| 2.2.4.1.1. The polymerase proteins (PB1, PB2 and PA) and PB1-F2 protein..... | 23         |
| 2.2.4.1.1.1. PB1 and PB1-F2.....                                             | 23         |
| 2.2.4.1.1.1.1. PB1.....                                                      | 23         |
| 2.2.4.1.1.1.2. PB1-F2.....                                                   | 24         |
| 2.2.4.1.1.2. PB2.....                                                        | 24         |

|                                                                                            |           |
|--------------------------------------------------------------------------------------------|-----------|
| 2.2.4.1.1.3.PA.....                                                                        | 25        |
| 2.2.4.1.2. Heamagglutinin protein (HA).....                                                | 26        |
| 2.2.4.1.3. Nucleocapsid protein (NP).....                                                  | 28        |
| 2.2.4.1.4. Neuraminidase protein (NA).....                                                 | 29        |
| 2.2.4.1.5. M proteins ((M <sub>1</sub> and M <sub>2</sub> )).....                          | 31        |
| 2.2.4.1.5.1. Matrix protein (M <sub>1</sub> ).....                                         | 31        |
| 2.2.4.1.5.2. Membrane protein (M <sub>2</sub> ).....                                       | 32        |
| 2.2.4.1.6. Nuclear export protein (NEP) or Nonstructural 2 protein (NS <sub>2</sub> )..... | 33        |
| 2.2.4.2. Nonstructural protein.....                                                        | 33        |
| 2.2.4.2.1. Nonstructural 1 protein (NS <sub>1</sub> ).....                                 | 33        |
| 2.2.5 Virus stability.....                                                                 | 37        |
| 2.2.5.1. Laboratory Situation.....                                                         | 37        |
| 2.2.5.2. Field Situation.....                                                              | 37        |
| <b>2.3. Diagnosis of avian influenza viruses.....</b>                                      | <b>38</b> |
| 2.3.1. Sample collection, Transportation, and Preservation.....                            | 38        |
| 2.3.2. Isolation and cultivation of the virus.....                                         | 40        |
| 2.3.2.1. Plaque assay.....                                                                 | 42        |
| 2.3.3. Serodiagnosis of H5N1 avian influenza virus.....                                    | 43        |
| 2.3.3.1. Serological assays mainly used in identification or subtyping of AI viruses.....  | 43        |
| 2.3.3.1.1. Heamagglutination inhibition test (HI).....                                     | 43        |
| 2.3.3.1.2. Neuraminidase inhibition test (NI).....                                         | 46        |
| 2.3.3.2. Serological assays mainly used in antibody detection.....                         | 46        |

|                                                                                                           |           |
|-----------------------------------------------------------------------------------------------------------|-----------|
| 2.3.3.2.1. Enzyme-linked immune-sorbent assay (ELISA).....                                                | 47        |
| 2.3.3.2.1.1. Cell-ELISA.....                                                                              | 48        |
| 2.3.4. Molecular diagnosis of H5N1 avian influenza virus.....                                             | 50        |
| 2.3.4.1. Reverse transcriptase-polymerase chain reaction (RT-PCR).....                                    | 50        |
| 2.3.4.2. Real-time RT-PCR (r RT-PCR).....                                                                 | 52        |
| 2.3.4.3. Nested PCR.....                                                                                  | 55        |
| 2.3.4.4. Sequencing of the virus genome .....                                                             | 56        |
| <b>2.4. Prevention and control.....</b>                                                                   | <b>59</b> |
| 2.4.1 Vaccination.....                                                                                    | 61        |
| 2.4.1.1. Types of AI vaccines.....                                                                        | 61        |
| 2.4.1.1.1. Live attenuated Avian Influenza Virus Vaccines.....                                            | 61        |
| 2.4.1.1.2. Inactivated Whole Avian Influenza Virus Vaccines.....                                          | 62        |
| 2.4.1.1.2.1. Homologous inactivated vaccines.....                                                         | 64        |
| 2.4.1.1.2.2. Heterologous inactivated vaccines.....                                                       | 65        |
| 2.4.1.1.3. Molecular- based vaccines.....                                                                 | 65        |
| 2.4.1.1.3.1. DNA Avian Influenza Virus Vaccines.....                                                      | 65        |
| 2.4.1.1.3.2. Live Recombinant Avian Influenza Vaccines....                                                | 66        |
| <b>3- MATERIAL AND METHODS.....</b>                                                                       | <b>71</b> |
| <b>3.1 The tested vaccines.....</b>                                                                       | <b>71</b> |
| <b>3.2. Detection of H5 gene insert in the tested vaccines by q real-time PCR (identity testing).....</b> | <b>71</b> |
| 3.2.1. Material.....                                                                                      | 71        |
| 3.2.1.1. The viruses.....                                                                                 | 71        |

|                                                                                                                                                              |           |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 3.2.1.2. Extraction kits.....                                                                                                                                | 71        |
| 3.2.1.2.1. QIA amp Viral Mini Kit (Qiagen kit).....                                                                                                          | 71        |
| 3.2.1.2.2. DNeasy Blood and tissue (Qiagen extraction kit)....                                                                                               | 72        |
| 3.2.1.3. Superscript III <sup>TM</sup> Platinum <sup>TM</sup> one-step q real-time PCR<br>system (Invitrogen kit).....                                       | 72        |
| 3.2.1.4. Oligonucleotide primers and probe.....                                                                                                              | 72        |
| 3.2.1.5. Nuclease free water (Sigma) .....                                                                                                                   | 73        |
| 3.2.1.6. Ethanol 75% (Sigma).....                                                                                                                            | 73        |
| 3.2.1.7. Equipments.....                                                                                                                                     | 73        |
| 3.2.2. Methods used for q real-time PCR.....                                                                                                                 | 74        |
| 3.2.2.1. RNA Extraction .....                                                                                                                                | 74        |
| 3.2.2.2. DNA extraction from the tested vaccine<br>samples.....                                                                                              | 75        |
| 3.2.2.3. Quantitative One-step real-time polymerase chain<br>reaction (q r RT-PCR).....                                                                      | 77        |
| <b>3.3. Preparation of H5N1 avian influenza virus hyper<br/>immune serum in rabbit.....</b>                                                                  | <b>78</b> |
| 3.3.1. Material.....                                                                                                                                         | 78        |
| 3.3.1.1. Inactivated oil adjuvant reasserted avian influenza<br>vaccine (H5N1 subtype, Re-5 strain produced by Merial<br>Nanjing Animal Health Co., ltd..... | 78        |
| 3.3.1.2. Rabbits.....                                                                                                                                        | 79        |
| 3.3.1.3. Equipments.....                                                                                                                                     | 79        |
| 3.3.2. Method.....                                                                                                                                           | 79        |
| <b>3.4. Detection of H5 antigen in the tested vaccine by<br/>ELISA.....</b>                                                                                  | <b>80</b> |
| 3.4.1. Material.....                                                                                                                                         | 80        |
| 3.4.1.1. CEF .....                                                                                                                                           | 80        |
| 3.4.1.2. Fetal bovine serum (Sigma).....                                                                                                                     | 80        |

|                                                                                                     |           |
|-----------------------------------------------------------------------------------------------------|-----------|
| 3.4.1.3. Minimum essential medium $\alpha$ (Gibco® MEM $\alpha$ , powder Catalog no. 12000014)..... | 81        |
| 3.4.1.3.1. Complete cell culture growth medium.....                                                 | 81        |
| 3.4.1.3.2. Maintenance growth medium.....                                                           | 81        |
| 3.4.1.4. Phosphate buffered saline (Sigma).....                                                     | 81        |
| 3.4.1.5. Fixation solution.....                                                                     | 82        |
| 3.4.1.6. Rabbit polyclonal anti AIV serum.....                                                      | 82        |
| 3.4.1.7. Goat anti- rabbit conjugate (Sigma).....                                                   | 82        |
| 3.4.1.8. Substrate buffer .....                                                                     | 82        |
| 3.4.1.9. Blocking buffer.....                                                                       | 83        |
| 3.4.1.10. Washing buffer.....                                                                       | 83        |
| 3.4.1.11. Dilution buffer for serum and conjugate.....                                              | 84        |
| 3.4.1.12. Stopping buffer .....                                                                     | 84        |
| 3.4.1.13. Reference negative control sera (anti-IBD and anti-Reo).....                              | 84        |
| 3.4.1.14. Recombinant HVT-ND, Marek's disease vaccine and Re-5 H5 AIV antigen.....                  | 84        |
| 3.4.1.15. Equipments.....                                                                           | 85        |
| 3.4.2. Methods.....                                                                                 | 85        |
| 3.4.2.1. Cell-ELISA procedure.....                                                                  | 85        |
| 3.4.2.2. H5-ELISA procedure.....                                                                    | 87        |
| <b>3.5. Vaccine safety.....</b>                                                                     | <b>91</b> |
| 3.5.1. Material.....                                                                                | 91        |
| 3.5.1.1. SPF chickens.....                                                                          | 91        |
| 3.5.1.2. Equipments.....                                                                            | 91        |
| 3.5.2. Method.....                                                                                  | 91        |